FREE CME | CMEList.com

 


The Evolution of Insulin Replacement Therapy: New Perspectives and Clinical Applications Free Diabetes CME
Live online September 14, 2017, October 19, 2017 and November 30, 2017 (2 sessions) and available on demand through May 30, 2018.
Posted by...Bernard Sklar, MD.
Free Diabetes CME Credit hours...4.0. 
CME Credits Awarded by....Joslin Diabetes Center.
Cost...........Free.
Instruction Type...Streaming Video Lecture and discussion.
Target Audiences...This program is intended for US-based primary care providers, clinical endocrinologists/diabetologists, nephrologists, cardiologists, emergency department specialists, pharmacists, and other clinicians caring for patients with type 2 diabetes mellitus (T2DM).
Educational material updated....September 14, 2017.
Expiration of CME credit...May 30, 2018.
Financial Support...Novo Nordisk Inc. and Medtronic, Inc.
The Evolution of Insulin Replacement Therapy consists of 4 presentations with discussion:
• Session 1: Insulin Options for Diabetes: Update on their Evolution
• Session 2: Advancing to Insulin Therapy for Type 2 Diabetes: The Impact of the New Insulin Options
• Session 3: Physiologic Insulin Replacement: Practical Approaches for the Primary Care Provider
• Session 4: The Evolution of Glycemic Monitoring and Insulin Delivery Devices: Why the Primary Care Provider Should Understand the Options
At the conclusion of The Evolution of Insulin Replacement Therapy, you will be able to:
• Identify clinically relevant pharmacokinetic and pharmacodynamic properties of the new insulins and insulin combinations
• Discuss the clinical importance of similarities and differences between a biosimilar insulin and a reference insulin
• Recognize the indications for advancement to insulin replacement therapy for people with T2DM
• Identify clinically relevant pharmacokinetic and pharmacodynamic properties of the new insulins and insulin combinations
• Describe initiation and titration methods for new insulin-based therapies to optimize achievement of glycemic goals while minimizing adverse effects
• Discuss strategies to overcome patient and clinician barriers to the successful initiation and utilization of insulin therapy in the context of the new insulin-based therapies, and monitoring and delivery devices

Pharmacotherapy of Obesity: Practical Applications for Clinical Care Free Diabetes CME
Live online June 7, 2017 and available on demand through December 7, 2017.
Posted by...Bernard Sklar, MD.
Free Obesity CME Credit hours..1.0.
CME Credits Awarded by....Boston University School of Medicine.
Cost...........Free.
Instruction Type...Streaming Video Lecture and discussion.
Target Audiences...This program is intended for family physicians, internists, endocrinologists, nurse practitioners, physician assistants and other health care providers of people who may be obese and need pharmacotherapeutic interventions.
Educational material updated....June 7, 2017.
Expiration of CME credit...December 7, 2017.
Financial Support...Novo Nordisk.
After viewing the three presentations of Pharmacotherapy of Obesity: Practical Applications for Clinical Care, you will be better able to:
• Identify obesity as a disease, not a behavioral problem, and consider the implications of that paradigm shift on attitudes toward treating the condition
• Identify indications that lifestyle interventions have not been sufficient to result in weight loss
• Describe the pharmacology of, and indications for, the use of the currently available medications for chronic weight management
• Describe ongoing management of people using anti-obesity medications, including means to gauge both therapeutic efficacy or the need to consider bariatric surgery

The Best of Stroke Forum 2016  Free Stroke CME
Posted by...Bernard Sklar, MD. 
Free CME Credit Hours...0.5.
CME Credits Awarded by...Vindico Medical Education.
Cost for Credit...Free.
Instruction Type...Video Lectures.
Target Audience...Emergency medicine physicians, neurologists, emergency medicine residents, nurses, physician assistants, nurse practitioners, and other health care professionals involved in the treatment of patients with AIS.
Educational material last updated...November 10, 2016.
CME Credit Expires...November 9, 2017.
Financial Support...Genentech, Inc.
The Best of Stroke Forum 2016 consists of two brief lectures:
• Eligibility for IV Thrombolysis: A Review of Inclusion and Exclusion Criteria
• Stroke Therapy: Examining New Evidence
After competing The Best of Stroke Forum 2016, you should be better able to:
• Apply evidence-based criteria to the selection of candidates for thrombolytic therapy in AIS.
• Evaluate FDA labeling, current data, and clinical practice guidelines on the use of tissue plasminogen activator in the extended 3-hour to 4.5-hour post-onset window.
• Assess recent studies and guidelines on endovascular procedures for AIS.
• Determine the criteria for the concomitant or preferential use of tissue plasminogen activator in patients with AIS who are being considered for endovascular procedures.
• Incorporate shared decision making with patients and their families to improve education and assist in reducing delays in treatment and complications.

How Low Can You Go? LDL - Is Lower Really Better?
Posted by...Bernard Sklar, MD. cholesterol CME
Free CME Credit Hours...1.0.
CME Credits Awarded by...Vindico Medical Education.
Cost for Credit...Free.
Instruction Type...Video Lectures.
Target Audience...Cardiologists, endocrinologists, primary care physicians, family physicians, internists, and other health care professionals involved in the treatment of patients with dyslipidemia.
Educational material last updated...August 25, 2016.
CME Credit Expires...August 24, 2017.
Financial Support...Amgen.
How Low Can You Go? LDL - Is Lower Really Better?  features interviews with clinical experts, who discuss newly released evidence and guidelines regarding cardiovascular risk assessment, best practices when evaluating patients with elevated LDL-C, clinical study data pertaining to the effects of lowering LDL-C beyond evidence-based recommendations, and use of non-statin therapies for the treatment of dyslipidemia in patients who cannot achieve desired target levels.
Upon successful completion of How Low Can You Go? LDL - Is Lower Really Better?, you should be better able to:
• Incorporate cardiovascular risk assessment, evidence-based guidelines, and best practices when evaluating patients with elevated LDL-C.
• Assess clinical study data pertaining to the effect of lowering LDL-C beyond evidence-based recommendations and its effect on cardiovascular risk reduction.
• Evaluate the use of non-statin therapies for the treatment of dyslipidemia in patients who are intolerant or in patients who cannot achieve desired target levels. • Incorporate therapeutic regimens with demonstrated ability to reduce risk markers other than LDL-C.
• Incorporate therapeutic regimens with demonstrated ability to reduce risk markers other than LDL-C.

The Newest in Non-Small Cell Lung Cancer (NSCLC): Emerging Therapies, Novel Approaches, Therapeutic Updates, and Barriers to Care and Incorporating Best Practice Lung Cancer CME
Posted by...Bernard Sklar, MD.  
Oncology CME Credit Hours...1.0.
CME Credits Awarded by....ScientiaCME.
Cost...........Free.
Instruction Type...Slide-Video Lectures.
Format...Online Video.
Target Audience...Healthcare professionals specializing in: interventional radiology; nuclear medicine; oncology; palliative care; pathology; pulmonology; or those who otherwise commonly care for patients with NSCLC.
Educational material last updated....May 9, 2016
Expiration of CME credit...May 9, 2018.
Financial Support...Boehringer Ingelheim.
The Newest in Non-Small Cell Lung Cancer (NSCLC) has been designed to bring your knowledge of the rationale behind treatment of NSCLC up to date and to enhance your competence in caring for patients with NSCLC. 
After viewing The Newest in Non-Small Cell Lung Cancer (NSCLC), you will be better able to:
• Describe the impact of biomarker and mutation testing and their results for the management of patients with NSCLC and apply this knowledge to patient cases.
• Describe the role and impact of the initial biopsy, including the relevance of its timing and factors affecting quality of results.
• Distinguish between different NSCLC disease subtypes on the basis of histology, biomarker, and mutation status and use the information to optimize care in the setting of patient cases.
• Discuss the ways that NSCLC has proved resistant to treatments in past and the mechanisms of action of targeted therapies, present and emerging.
In order to get credit from ScientiaCME, you must first establish a username and password.

Alzheimer Disease (AD) and Its Complications: Best Practices, Emerging Therapies, and Barriers to Care Alzheimer's Disease CME
Posted by...Bernard Sklar, MD.
Alzheimer's Disease CME Credit hours...1.0.
CME Credits Awarded by....ScientiaCME.
Cost...........Free.
Instruction Type...Streaming Video Lecture.
Target Audiences...Healthcare professionals specializing in: neurology, gerontology, internal medicine, palliative care, or those who otherwise commonly care for patients with AD or who frequently encounter them or their caregivers in practice.
Educational material updated...December 21, 2015.
Expiration of CME credit...December 21, 2017.
Financial Support...AVANIR.
Topics covered in Alzheimer Disease (AD) and Its Complications include:
Epidemiology of and risk factors for Alzheimer Disease (AD), Symptomatology and diagnosis of AD, Treatment in patients with AD, Complications and barriers to optimal care in patients with AD and many more.
After completing Alzheimer Disease (AD) and Its Complications, you will be able to:
• Describe what is presently known about the pathophysiology of AD and the challenges associated with diagnosis and treatment of AD.
• Evaluate a treatment plan for a specific patient based on degree of AD to optimize safety and efficacy, suggesting modifications for improvement.
• Identify the present treatment options currently available for management of AD and apply them to patient cases using evidence-based medicine.
• Describe emerging drug therapies in the treatment of AD.
• Describe barriers to care and suggest therapies for treating cognitive and behavioral complications secondary to AD